US scientific services supplier Thermo Fisher Scientific has opened a new 72,500-square-foot clinical research laboratory building at its good manufacturing practices (GMP) lab in Middleton, Wisconsin, USA.
Thermo Fisher Scientific has completed the acquisition of CorEvitas, a provider of registry data and analytic services, from Audax Private Equity for $912.5 million in cash.
US scientific services supplier Thermo Fisher Scientific has agreed to acquire CorEvitas, a provider of registry data and analytic services, from Audax Private Equity for $912.5 million in cash. The transaction, which is expected to be completed by the end of 2023, is subject to customary closing conditions, including regulatory approvals.
A private equity consortium of Warburg Pincus and Advent International is said to be in advanced talks to acquire medical device maker Baxter International’s biopharma solutions business. The deal could be worth $4 billion or more, news agencies and the newspaper Wall Street Journal reported.
Plans by US healthcare company Baxter International to shed its biopharma contract business as it streamlines operations after a poor 2022 earnings performance are gradually taking concrete shape.
Thermo Fisher Scientific has completed the planned expansion of its US dry powder media manufacturing capacity in Grand Island, New York, which it said is designed to meet increasing global demand for cell culture media used in the manufacturing of new vaccines and biologics.
Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of the major investments by the larger CMDOs/CMOs are outlined in this article.
US scientific services supplier Thermo Fisher Scientific is investing $82.5 million to expand operations and create 169 jobs at its biologic drug substance manufacturing plant in St. Louis County, Missouri. The expanded facility will manufacture biologic drug substance products for treating a variety of chronic health conditions, including cancers and other life-threatening diseases, as well as Covid-19.
As it ramps up production on three continents, US Covid-19 vaccine manufacturer Moderna is expanding its collaborations with CDMO suppliers in Europe, the US and Asia. At the beginning of June, the US biotech announced new supply agreements with Lonza and Thermo-Fisher. In late May, it inked new deals with Aldevron and Samsung Biologics in Asia to handle various stages of the mRNA shot’s production.
Thermo Fisher Scientific plans to spend more than $600 million to upgrade its bioprocessing operations up to 2022. It aims to more than double current manufacturing capacity and support biopharma customers as they ramp up to meet short-term demands related to COVID-19. Another goal is to support its own long-term efforts to develop new vaccines and biologics for other conditions.
In another move to boost its position in diagnostics for Covid-19 and other infectious diseases, Thermo Fisher Scientific has signed a definitive agreement to acquire privately held molecular diagnostic company Mesa Biotech for $450 million in cash. The business will become part of its Life Sciences Solutions segment.
To support worldwide development of Covid-19 drugs and vaccines, CDMO Thermo Fisher Scientific is investing in new facilities for its cell and gene therapy portfolio in both the US and Europe.
US scientific equipment manufacturer Thermo Fisher Scientific and China-based CDMO Innoforce have formed a joint venture to own and operate a new pharma services facility for integrated biologics and sterile drug development and manufacturing in Hangzhou, China. Start date for the new entity is 2022.
So far, the pharmaceutical industry — including CMOs/CDMOs — has responded well to the outbreak of the Covid-19 pandemic.
To help meet surging demand for Covid-19 diagnostics, US diagnostic specialist Thermo Fisher Scientific has completed a new $40 million production plant for viral transport media at its Lenexa, Kansas, site in a record six weeks.
To save manufacturing space for its growing vaccines plans, Pfizer has said it will outsource production of some of its pharmaceutical portfolio. The work is planned to be shared out with a network of 200 contractors in the US and Europe.
